Healthcare Industry News:  InterMune 

Biopharmaceuticals Personnel

 News Release - December 6, 2006

Epiphany Biosciences Appoints Brian Murphy as Chief Medical Officer

SAN FRANCISCO, Dec. 6 (HSMN NewsFeed) -- Epiphany Biosciences Inc. announced today the appointment of Brian Murphy, M.D., MPH, MBA, as Chief Medical Officer. Dr. Murphy is a distinguished virologist and hepatologist with more than 15 years of experience in the global development of novel anti-viral therapeutics. Dr. Murphy joins Epiphany from Valeant Pharmaceuticals International where he served as Chief Medical Officer and Vice President, Global Medical Affairs, and was responsible for the company's development programs. Prior to Valeant, Dr. Murphy held senior management positions at InterMune and Roche Pharmaceuticals where he oversaw the clinical development and launch of four products.

Dr. Murphy obtained his medical degree from New York Medical College. He completed his MPH at the Harvard school of Public Heath while serving as a Clinical Research Fellow in General Medicine at Massachusetts General Hospital.

Robert Gallo MD, Epiphany co-founder, eminent virologist, and co-discoverer of HIV and HTLV, stated, "We are fortunate to have Dr Murphy. He is highly qualified and he is perfectly suited for the direction that the company should be going and is going."

"I second Dr Gallo's sentiments about Brian," noted Epiphany founder and CEO Fred Volinsky, MD. "We are elated to have Dr. Murphy lead our Clinical Affairs team. He has spent his career working on the development of anti-viral drugs and has provided critical leadership on four NDA's. Besides his superb medical background, Brian brings both excellent business acumen and market sense to Epiphany, and he is a great addition to our management team. We believe that our ability to recruit such a highly qualified Chief Medical Officer from a large public company validates both our programs and our vision," continued Volinsky.

"I am honored to join a company of scientists and management with a tremendous track record of achievement who appreciate the potential of Epiphany's therapeutic model in curing disease and improving the quality of life for patients," said Dr. Murphy.

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. Epiphany's team includes a world-class group of virologists. The founders include Fred Volinsky MD, Robert Gallo MD, David Myles Ph.D. and Barry Selick Ph.D. Epiphany is located in San Francisco, California. Additional information on Epiphany Biosciences may be obtained at the company website or by contacting company representatives: Fred G. Volinsky MD, CEO 415.765.7193; David C. Myles Ph.D., COO 415.765.7198.

Source: Epiphany Biosciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.